ABSTRACT
BACKGROUND: Transplant renal artery stenosis (TRAS) may lead to graft dysfunction and failure. Progressive deterioration of renal allograft function may be exacerbated by contrast-induced nephrotoxicity during iodine contrast administration for renovascular imaging of allografts. We present our institutional experience of endovascular management for TRAS using CO2 digital subtraction angiography (CO2-DSA) and balloon angioplasty to manage failing renal transplants. METHODS: Four patients with renal allografts from March 2017-May 2018 were referred for graft dysfunction and pending renal transplant failure. Indications for referral included refractory hypertension, decreasing renal functioning, and elevated renovascular systolic velocities. RESULTS: Median age of the four patients was 41.5 years (22-60 years). There were two male and female patients. Chronic hypertension and type 2 diabetes mellitus were the most common comorbidities. An average total of 75 mL of CO2 was used, supplemented with 17.4 mL of iodinated contrast. All patients had improvements in renal function following intervention with a mean decrease in systolic and diastolic blood pressure of 25.8% and 21.4%, respectively. We also observed a mean decrease of BUN by 13.6% and creatinine by 37.4%. Additionally, eGFR increased by 37.7%. All allografts survived after surgery, and only one patient required repeat angioplasty for recurrence. CONCLUSIONS: CO2-DSA with balloon angioplasty can be successfully utilized to salvage deteriorating kidney allograft function in patients with TRAS.
Subject(s)
Angiography, Digital Subtraction , Angioplasty, Balloon , Carbon Dioxide/administration & dosage , Contrast Media/administration & dosage , Kidney Transplantation/adverse effects , Renal Artery Obstruction/diagnostic imaging , Renal Artery Obstruction/therapy , Renal Artery/diagnostic imaging , Adult , Angiography, Digital Subtraction/adverse effects , Angioplasty, Balloon/adverse effects , Blood Pressure , Carbon Dioxide/adverse effects , Contrast Media/adverse effects , Female , Glomerular Filtration Rate , Graft Survival , Humans , Male , Middle Aged , Predictive Value of Tests , Recovery of Function , Recurrence , Renal Artery/physiopathology , Renal Artery Obstruction/etiology , Renal Artery Obstruction/physiopathology , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Vascular Patency , Young AdultABSTRACT
AIM: The aim of the study is to determine whether the apparent benefit of revascularization of renal artery stenosis for 'flash' pulmonary oedema extends to heart failure patients without a history of prior acute pulmonary oedema. METHODS: A prospective study of patients with renal artery stenosis and heart failure at a single centre between 1 January 1995 and 31 December 2010. Patients were divided into those with and without previous acute pulmonary oedema/decompensation. Survival analysis compared revascularization versus medical therapy in each group using Cox regression adjusted for age, estimated glomerular filtration rate, blood pressure and co-morbidities. RESULTS: There were 152 patients: 59% male, 36% diabetic, age 70 ± 9 years, estimated glomerular filtration rate 29 ± 17 mL/min per 1.73 m2 ; 52 had experienced previous acute pulmonary oedema (34%), whereas 100 had no previous acute pulmonary oedema (66%). The revascularization rate was 31% in both groups. For heart failure without previous acute pulmonary oedema, the hazard ratio for death after revascularization compared with medical therapy was 0.76 (0.58-0.99, P = 0.04). In heart failure with previous acute pulmonary enema, the hazard ratio was 0.73 (0.44-1.21, P = 0.22). For those without previous acute pulmonary oedema, the hazard ratio for heart failure hospitalization after revascularization compared with medical therapy was 1.00 (0.17-6.05, P = 1.00). In those with previous acute pulmonary oedema, it was 0.51 (0.08-3.30, P = 0.48). CONCLUSION: The benefit of revascularization in heart failure may extend beyond the current indication of acute pulmonary oedema. However, findings derive from an observational study.
Subject(s)
Angioplasty , Cardio-Renal Syndrome/complications , Heart Failure/complications , Pulmonary Edema/etiology , Renal Artery Obstruction/therapy , Acute Disease , Aged , Aged, 80 and over , Angioplasty/adverse effects , Angioplasty/instrumentation , Angioplasty/mortality , Cardio-Renal Syndrome/diagnosis , Cardio-Renal Syndrome/mortality , Cardio-Renal Syndrome/physiopathology , Chi-Square Distribution , Chronic Disease , Comorbidity , Female , Heart Failure/diagnosis , Heart Failure/mortality , Heart Failure/physiopathology , Humans , Male , Middle Aged , Proportional Hazards Models , Pulmonary Edema/diagnosis , Pulmonary Edema/mortality , Pulmonary Edema/physiopathology , Renal Artery Obstruction/diagnosis , Renal Artery Obstruction/mortality , Renal Artery Obstruction/physiopathology , Retrospective Studies , Risk Factors , Stents , Time Factors , Treatment OutcomeABSTRACT
Results of recent clinical trials and experimental studies indicate that whereas atherosclerotic renovascular disease can accelerate both systemic hypertension and tissue injury in the poststenotic kidney, restoring vessel patency alone is insufficient to recover kidney function for most subjects. Kidney injury in atherosclerotic renovascular disease reflects complex interactions among vascular rarefication, oxidative stress injury, and recruitment of inflammatory cellular elements that ultimately produce fibrosis. Classic paradigms for simply restoring blood flow are shifting to implementation of therapy targeting mitochondria and cell-based functions to allow regeneration of vascular, glomerular, and tubular structures sufficient to recover, or at least stabilize, renal function. These developments offer exciting possibilities of repair and regeneration of kidney tissue that may limit progressive CKD in atherosclerotic renovascular disease and may apply to other conditions in which inflammatory injury is a major common pathway.
Subject(s)
Atherosclerosis/complications , Kidney/pathology , Nephritis/pathology , Renal Artery Obstruction/complications , Renal Insufficiency, Chronic/therapy , Hemodynamics , Humans , Ischemia/etiology , Kidney/blood supply , Mitochondria , Nephritis/etiology , Oxidative Stress , Renal Artery Obstruction/physiopathology , Renal Circulation , Renal Insufficiency, Chronic/etiology , Renal Insufficiency, Chronic/prevention & controlABSTRACT
PURPOSE: The activation of the renin-angiotensin-aldosterone system caused by renal ischaemia in atherosclerotic renal artery stenosis (ARAS) may be responsible for serious cardiovascular and renal consequences. The aim of the study was to assess the long-term safety, tolerability and outcomes of the use of angiotensin I-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) in patients with ARAS. METHODS: Thirty-six patients with angiographically defined ARAS (managed either with revascularization or only with medical treatment) were prospectively assessed for the safety, tolerability and outcomes of the use of ACEis or ARBs. RESULTS: The mean period of follow-up was 88.9 ± 37.8 months. A statistically significant reduction in systolic and diastolic blood pressure was recorded over time (P < 0.001). While estimated glomerular filtration rate remained almost stable during the study period (0.816), nuclear EDTA-GFR showed a significant reduction over time (P = 0.03). Mean time from diagnosis/intervention to end-stage renal disease for the cohort of 36 patients was 165.38 ± 13.62 months. Mean overall patient survival was 135.36 ± 15.25 months, with fourteen deaths (38.8%) occurring during the observational period. ACEi/ARB therapy was discontinued transiently in only 4 subjects. CONCLUSIONS: The use of ACEis/ARBs is safe and effective in patients with ARAS independently of any parameters.
Subject(s)
Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Atherosclerosis/complications , Blood Pressure/drug effects , Renal Artery Obstruction/physiopathology , Renal Artery Obstruction/therapy , Adult , Aged , Aged, 80 and over , Angioplasty , Angiotensin Receptor Antagonists/adverse effects , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Cardiovascular Diseases/etiology , Disease Progression , Female , Follow-Up Studies , Glomerular Filtration Rate/drug effects , Humans , Kaplan-Meier Estimate , Kidney Failure, Chronic/etiology , Male , Middle Aged , Proportional Hazards Models , Prospective Studies , Renal Artery Obstruction/complications , Renin-Angiotensin System/drug effects , Time FactorsABSTRACT
INTRODUCTION: Renal artery stenosis can lead to renovascular hypertension; however, the detection of stenosis alone does not guarantee the presence of renovascular hypertension. Renovascular hypertension depends on activation of the renin-angiotensin system, which can be detected by functional tests such as captopril renal scintigraphy. A method that allows direct measurement of the baseline and post-captopril glomerular filtration rate using chromium-51 labeled ethylenediamine tetraacetic acid ((51)Cr-EDTA) could add valuable information to the investigation of hypertensive patients with renal artery stenosis. The purposes of this study were to create a protocol to measure the baseline and post-captopril glomerular filtration rate using (51)Cr-EDTA, and to verify whether changes in the glomerular filtration rate permit differentiation between hypertensive patients with and without renal artery stenosis. METHODS: This prospective study included 41 consecutive patients with poorly controlled severe hypertension. All patients had undergone a radiological investigation of renal artery stenosis within the month prior to their inclusion. The patients were divided into two groups: patients with (n=21) and without renal artery stenosis, (n=20). In vitro glomerular filtration rate analysis ((51)Cr-EDTA) and (99m)Tc-DMSA scintigraphy were performed before and after captopril administration in all patients. RESULTS: The mean baseline glomerular filtration rate was 48.6+/-21.8 ml/kg/1.73 m(2) in the group wuth renal artery stenosis, which was significantly lower than the GFR of 65.1+/-28.7 ml/kg/1.73m(2) in the group without renal artery stenosis (p=0.04). Captopril induced a significant reduction of the glomerular filtration rate in the group with renal artery stenosis (to 32.6+/-14.8 ml/ kg/1.73m(2), p=0.001) and an insignificant change in the group without RAS (to 62.2+/-23.6 ml/kg/1.73m(2), p=0.68). Scintigraphy with technetium-99m dimercapto-succinic acid (DMSA) did not show significant differences in differential renal function from baseline to post-captopril images in either group. CONCLUSIONS: Captopril induced a decrease in the GFR that could be quantitatively measured with (51)Cr-EDTA. The reduction is more pronounced in hypertensive patients with RAS.
Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Captopril/therapeutic use , Chelating Agents , Edetic Acid , Glomerular Filtration Rate/radiation effects , Hypertension, Renovascular/diagnostic imaging , Renal Artery Obstruction/physiopathology , Chelating Agents/pharmacokinetics , Edetic Acid/pharmacokinetics , Female , Humans , Male , Middle Aged , Prospective Studies , Radionuclide Imaging , Renal Artery Obstruction/metabolism , Technetium Tc 99m Dimercaptosuccinic Acid/pharmacokineticsABSTRACT
INTRODUCTION: Renal artery stenosis can lead to renovascular hypertension; however, the detection of stenosis alone does not guarantee the presence of renovascular hypertension. Renovascular hypertension depends on activation of the renin-angiotensin system, which can be detected by functional tests such as captopril renal scintigraphy. A method that allows direct measurement of the baseline and post-captopril glomerular filtration rate using chromium-51 labeled ethylenediamine tetraacetic acid (51Cr-EDTA) could add valuable information to the investigation of hypertensive patients with renal artery stenosis. The purposes of this study were to create a protocol to measure the baseline and post-captopril glomerular filtration rate using 51Cr-EDTA, and to verify whether changes in the glomerular filtration rate permit differentiation between hypertensive patients with and without renal artery stenosis. METHODS: This prospective study included 41 consecutive patients with poorly controlled severe hypertension. All patients had undergone a radiological investigation of renal artery stenosis within the month prior to their inclusion. The patients were divided into two groups: patients with (n=21) and without renal artery stenosis, (n=20). In vitro glomerular filtration rate analysis (51Cr-EDTA) and 99mTc-DMSA scintigraphy were performed before and after captopril administration in all patients. RESULTS: The mean baseline glomerular filtration rate was 48.6±21.8 ml/kg/1.73 m² in the group wuth renal artery stenosis, which was significantly lower than the GFR of 65.1±28.7 ml/kg/1.73m² in the group without renal artery stenosis (p=0.04). Captopril induced a significant reduction of the glomerular filtration rate in the group with renal artery stenosis (to 32.6±14.8 ml/kg/1.73m², p=0.001) and an insignificant change in the group without RAS (to 62.2±23.6 ml/kg/1.73m², p=0.68). Scintigraphy with technetium-99m dimercapto-succinic acid (DMSA) did...
Subject(s)
Female , Humans , Male , Middle Aged , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Captopril/therapeutic use , Chelating Agents , Edetic Acid , Glomerular Filtration Rate/radiation effects , Hypertension, Renovascular , Renal Artery Obstruction/physiopathology , Chelating Agents/pharmacokinetics , Edetic Acid/pharmacokinetics , Prospective Studies , Renal Artery Obstruction/metabolism , /pharmacokineticsSubject(s)
Abdominal Pain/etiology , Renal Artery Obstruction/complications , Renal Insufficiency/physiopathology , Transaminases/analysis , Weight Lifting , Acute Disease , Adult , Dietary Supplements , Doping in Sports , Humans , Male , Oklahoma , Renal Artery Obstruction/physiopathology , Transaminases/bloodABSTRACT
Reactive oxygen species (ROS) can modulate renal hemodynamics and function both directly, by leading to vasoconstriction, and indirectly, by inducing renal inflammation and tissue growth. The involvement of oxidative stress in the pathogenesis of renovascular disease (RVD) is increasingly recognized, but the relative contribution of long-term tissue injury to renal dysfunction remains unclear. We hypothesized that functional and structural alterations elicited by oxidative stress in RVD would be more effectively modulated by chronic than by acute antioxidant intervention. Renal hemodynamics and function were quantified in vivo in pigs using electron-beam computed tomography at baseline and after vasoactive challenge (ACh and sodium nitroprusside); after 12 wk of RVD (simulated by concurrent hypercholesterolemia and renal artery stenosis, n = 7); RVD acutely infused with the SOD-mimetic tempol (RVD+tempol, n = 7); RVD chronically supplemented with antioxidant vitamins C (1 g) and E (100 IU/kg; RVD+vitamins, n = 7); or control (normal, n = 7). Renal tissue was studied ex vivo using immunoblotting and immunohistochemistry. Basal renal blood flow (RBF) and glomerular filtration rate were similarly decreased in all RVD groups. ACh-stimulated RBF remained unchanged in RVD, increased in RVD+tempol, but further increased (similarly to normal) in RVD+vitamins (P < 0.05 vs. RVD). Furthermore, RVD+vitamins also showed a decreased presence of superoxide anion, decreased NAD(P)H-oxidase and nitrotyrosine expression, increased endothelial nitric oxide synthase expression, and attenuated renal fibrosis. Chronic antioxidant intervention in early RVD improved renal hemodynamic responses more effectively than acute intervention, likely due to increased nitric oxide bioavailability and decreased structural injury. These suggest that chronic tissue changes play an important role in renal compromise mediated by oxidative stress in RVD.
Subject(s)
Antioxidants/therapeutic use , Hypertension, Renovascular/drug therapy , Acetylcholine/pharmacology , Acute Disease , Animals , Ascorbic Acid/therapeutic use , Blotting, Western , Chronic Disease , Cyclic N-Oxides/therapeutic use , Glomerular Filtration Rate/physiology , Hypertension, Renovascular/pathology , Hypertension, Renovascular/physiopathology , In Vitro Techniques , Kidney Function Tests , Kidney Tubules/physiology , Nitroprusside/pharmacology , Oxidative Stress/drug effects , Renal Artery Obstruction/physiopathology , Renal Circulation/drug effects , Spin Labels , Superoxide Dismutase/therapeutic use , Swine , Tomography, X-Ray Computed , Vasodilator Agents/pharmacology , Vitamin E/therapeutic useABSTRACT
Renal artery stenosis (RAS) may lead to renal injury, partly mediated through increased oxidative stress. However, the potential effects of chronic oral antioxidant intervention on the stenotic kidney remain unknown. This study was designed to test the hypothesis that chronic antioxidant vitamin supplementation in RAS would preserve renal function and structure. Single-kidney hemodynamics and function were quantified in vivo in pigs using electron-beam CT after 12 weeks of unilateral RAS (n=7), a similar degree of RAS orally supplemented with vitamins C (1 g) and E (100 IU/kg) (RAS+Vitamins, n=7), or controls (normal, n=7). Renal tissue was studied ex vivo using Western blotting and immunohistochemistry. Mean arterial pressure was similarly elevated in both RAS groups, while ischemic renal volume and glomerular filtration rate were similarly reduced. Renal blood flow was decreased in RAS compared with normal (326.5+/-99.9 versus 553.4+/-48.7 mL/min, respectively, P=0.01), but preserved in RAS+Vitamins (485.2+/-104.1 mL/min, P=0.3 versus normal). The marked increase in the expression of the NADPH-oxidase subunits p47phox and p67phox, nitrotyrosine, endothelial and inducible nitric oxide synthase, and nuclear factor-kappaB observed in RAS (P<0.05 versus normal) was normalized in RAS+Vitamins (P>0.1). Furthermore, trichrome staining and the expression of transforming growth factor-beta and tissue inhibitor of matrix-metalloproteinase-1 were also decreased in RAS+Vitamins. In conclusion, chronic blockade of the oxidative stress pathway in RAS using antioxidant vitamins improved renal hemodynamics and decreased oxidative stress, inflammation, and fibrosis in the ischemic kidney. These observations underscore the involvement of oxidative stress in renal injury in RAS and support a role for antioxidant vitamins in preserving the ischemic kidney.
Subject(s)
Antioxidants/therapeutic use , Ascorbic Acid/therapeutic use , Renal Artery Obstruction/drug therapy , Vitamin E/therapeutic use , Animals , Fibrosis , Hemodynamics , Inflammation/drug therapy , Kidney/blood supply , Kidney/pathology , Kidney/physiopathology , Oxidation-Reduction , Oxidative Stress/drug effects , Regional Blood Flow , Renal Artery Obstruction/pathology , Renal Artery Obstruction/physiopathology , SwineABSTRACT
Studies were performed in oliguric and nonoliguric forms of uranyl acetate (UA)-induced and ischemic acute renal failure (ARF) to examine whether a reduction in GFR is correlated with glomerular morphologic alterations. UA-induced nonoliguric and oliguric ARF were induced in rabbits by i.v. injections of 0.9 and 2 mg/kg, respectively. A 60-min renal artery clamping produced nonoliguric ARF in previously uninephrectomized rats, but oliguric ARF in the clamped kidneys of sham-nephrectomized animals. A decline in the whole-kidney CIn rate was more marked in oliguric ARF kidneys of both models than in nonoliguric ARF kidneys. Also, tubular damage was more pronounced in oliguric kidneys when compared with nonoliguric kidneys. Scanning electron microscopic observations revealed glomerular alterations in oliguric and nonoliguric kidneys in both models, evidenced by a flattening and spreading of podocyte cell bodies associated with loss of epithelial foot processes and a reduction in the density and diameter of endothelial fenestrae. There was no significant difference in these glomerular changes between oliguric and nonoliguric kidneys. The findings suggest that less reduction in the whole-kidney GFR in nonoliguric ARF kidneys is ascribed largely to less pronounced tubular damage rather than to less severe glomerular morphologic alterations.
Subject(s)
Acute Kidney Injury/physiopathology , Kidney Glomerulus/physiopathology , Oliguria/physiopathology , Acute Kidney Injury/epidemiology , Acute Kidney Injury/etiology , Analysis of Variance , Animals , Disease Models, Animal , Glomerular Filtration Rate , Kidney Glomerulus/ultrastructure , Male , Microscopy, Electron, Scanning , Nephrectomy , Oliguria/epidemiology , Oliguria/etiology , Organometallic Compounds , Rabbits , Rats , Rats, Sprague-Dawley , Renal Artery Obstruction/complications , Renal Artery Obstruction/epidemiology , Renal Artery Obstruction/physiopathology , UraniumABSTRACT
Acute renal failure was induced in pentobarbital anesthetized dogs either by withdrawal of the blood and/or by acute renal artery occlusion and efficacy of felodipine in preserving renal function was evaluated. In Wiggers' model of hemorrhagic shock, animals were allowed to bleed into a reservoir and after maintaining a hypotensive state (40-45 mm Hg) for 150 minutes, blood was reinfused and recovery in the renal function was evaluated. In a separate series, a renal artery was completely occluded for 45 minutes and after release of the occlusion recoveries in various markers of renal function were monitored. Felodipine 0.01 mumol/kg i.v. or the vehicle was administered ten minutes before hemorrhage or ten minutes prior to initiation of renal artery occlusion. Comparison of the data between the vehicle-treated dogs from the two models show that although renal blood flow (RBF) was restored to similar levels, recoveries in glomerular filtration rate (GFR), urine volume (UV), urinary excretion of sodium (UNa V) and potassium (UK V) were severely depressed in shock model (15 to 25% of the basal value) and consistently lower than the recoveries in the renal artery occlusion model (30-50%). These data could suggest that the extent of renal impairment is more severe in hemorrhagic shock. Nevertheless, felodipine pretreatment provided significant protection to renal function from ischemic damage in both the models; the drug-treated groups were characterized by significant recoveries in GFR, UNa V and UK V (60-100%) and by prompt and full restoration of RBF and UV.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Acute Kidney Injury/prevention & control , Felodipine/pharmacology , Acute Kidney Injury/etiology , Animals , Disease Models, Animal , Dogs , Drug Evaluation, Preclinical , Female , Glomerular Filtration Rate/drug effects , Kidney/drug effects , Kidney/physiopathology , Male , Renal Artery Obstruction/complications , Renal Artery Obstruction/physiopathology , Renal Circulation/drug effects , Shock, Hemorrhagic/complications , Shock, Hemorrhagic/physiopathologySubject(s)
Blood Pressure/drug effects , Enkephalin, Leucine-2-Alanine/analogs & derivatives , Enkephalin, Leucine/analogs & derivatives , Hypertension, Renovascular/drug therapy , Myocardial Contraction/drug effects , Stress, Psychological/drug therapy , Systole/drug effects , Animals , Chronic Disease , Drug Evaluation, Preclinical , Enkephalin, Leucine/therapeutic use , Hypertension, Renovascular/physiopathology , Male , Rats , Renal Artery Obstruction/drug therapy , Renal Artery Obstruction/physiopathology , Stress, Psychological/physiopathologyABSTRACT
The increase in arterial pressure and vascular resistance during acute unilateral renal artery stenosis (RSt) in conscious rats is, in part, dependent on elevated neurogenic vascular tone produced by an indirect neural interaction of angiotensin II (ANG II) with the sympathetic nervous system. The present experiments examined whether this interaction occurs within the central nervous system. Conscious rats that had been chronically instrumented with miniaturized Doppler flow probes for measurement of regional vascular resistance were subjected to a 50% reduction in unilateral renal flow with an implanted pneumatic occluder. Arterial pressure increased by 35% after 60 min of RSt. In animals in which the pressor response to intracerebroventricular (icv) ANG II had been eliminated by prior surgical interruption of the "ANG II pressor pathway" in the anterior hypothalamus, the increase in blood pressure following RSt was attenuated by 44% (P less than 0.01). In a second series, a central action of ANG II during acute renal hypertension (RH) was assessed by central ANG II receptor blockade with icv saralasin. Unlike normotensive controls, acutely RH animals responded to saralasin with significant (P less than 0.01) decreases in arterial pressure (-32%) and hindquarters (-26%) and contralateral renal (-9%) resistance. These changes were accentuated (-57% decrease in pressure) in animals made areflexic by prior sinoaortic baroreceptor denervation. Thus activation of the sympathetic nervous system during the early high-renin phase of RH depends significantly on a central action of ANG II. This mechanism may account for some 40-50% of the pressure increase following acute RSt.